A Safety/Efficacy Study of a Non-steroid, Topical Cream Treatment of Psoriasis Over 12-weeks

Psoriasis Clinical Trial

— 134993  

Official title:

A Double-blinded, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Topically Applied 1.0% WBI-1001 Cream for 12 Weeks, in the Treatment of Mild to Moderate Plaque Psoriasis.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01098721
• Other study ID #: WBI-1001-102
• Secondary ID: 134993
• Status: Completed
• Phase: Phase 2
• First received: April 1, 2010
• Last updated: December 18, 2012
• Start date: January 2010
• Est. completion date: November 2010

Study information

• Verified date: December 2012
• Source: Welichem Biotech Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

Psoriasis is a chronic inflammatory skin disorder that is characterized by hyperproliferation of the keratinocytes and inflammation of the epidermal and dermal layers of the skin. This study, in patients with mild to moderate plaque psoriasis, is designed to further determine the efficacy, safety and tolerability of the novel, topically applied, non-steroid, anti-inflammatory WBI-1001 cream over a period of 12 weeks.

Description:

A double-blinded, placebo-controlled study. Following screening, eligible patients will be randomized on Day 0 into one of two treatment groups in a 1:2 ratio:

Group 1: placebo (vehicle) cream, twice daily (BID). Group 2: 1.0% WBI-1001 cream, BID. Patients will be randomized to treat all treatable lesion areas except for the face, scalp, groin and genital areas, and will be instructed to apply the cream twice daily for 84 days, at the same time each day, once in the morning and once in the evening.

During the study patients will visit the study centre for assessment of efficacy, safety and tolerability at 0, 14, 28, 56 and 84 days after initiation, and patients will be phoned at Day 112 for a follow-up safety assessment.

Patients that withdraw from the study before Day 56 due to reasons other than adverse events will be replaced as necessary to ensure that there are at least 16 patients from the placebo and 32 from the active cream treated groups remaining in the study at Day 56.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 61
• Est. completion date: November 2010
• Est. primary completion date: September 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• A clinical diagnosis of stable plaque psoriasis for at least 6 months representing a maximum of 10% of BSA with a minimum of 1% BSA excluding the face, groin ,scalp and genital regions and with a minimum of one target plaque that is at least 2 x 2 cm in size at Day 0.

• PGA of 2 to 4 at Day 0.

• In good general health and free of any disease state or physical condition that might impair the evaluation of plaque psoriasis.

• Women of child bearing potential (WOCBP) must have a negative serum beta-human chorionic gonadotrophin (b-hCG) pregnancy test before randomization. WOBCP who are not abstinent from sex with male partners may be entered into the study if they are willing to continue to use adequate contraceptive precautions for the duration of the study. Male patients with female sexual partners who are able to become pregnant must ensure that an acceptable method of birth control is used while they are in the study. Women who are lactating will not be eligible for the study.

• Willing and able to comply with the protocol and likely to attend all study visits.

• Provide written, informed consent prior to the initiation of any study-related procedures.

Exclusion Criteria:

• Spontaneously improving or rapidly deteriorating plaque psoriasis.

• Any other skin diseases that might interfere with the clinical assessment of plaque psoriasis and/or put the patient at risk.

• Pustular, erythrodermic or other non-plaque forms pf psoriasis.

• Guttate psoriasis as the dominant form of psoriasis.

• Other concomitant, serious illness or medical condition (eg., human immunodeficiency virus, renal insufficiency, clinically significant abnormal laboratory values) that could put the patient at risk during the study.

• History of neurological/psychiatric disorders, including psychotic disorders or dementia, or any other reason that would interfere with the patient's participation in the trial.

• Systemic immunomodulatory therapy known to affect psoriasis and decreases immune cell populations (eg., alefacept) within 24 weeks of the baseline visit.

• Systemic immunomodulatory therapy known to affect psoriasis and that does not typically decrease immune cell populations (eg., etanercept) within 12 weeks prior to the baseline visit.

• Any phototherapy (including laser for the treatment of psoriasis), photo-chemotherapy,or systemic psoriasis therapy (such as systemic corticosteroids, methotrexate, retinoids or cyclosporine) within 4 weeks prior to the baseline visit.

• Prolonged exposure to artificial or natural sources of ultraviolet radiation within 4 weeks prior to the baseline visit or intention to have such exposure during the study, thought by the investigator likely to modify the patient's psoriasis.

• Topical anti-psoriatic therapy (including topical retinoids and vitamin D analogs) on the areas to be treated within 2 weeks prior to the baseline visit.

• Alcohol abuse during the last 2 years as defined by the consumption of >14 standard drinks of alcohol per week.

• Use of lithium within 2 weeks prior to the screening visit.

• Use of beta blockers (eg., propranolol) within 2 weeks prior to the screening visit unless on a stable dose for >3 months.

• Known or suspected hypersensitivity to any of the constituents of the investigational product.

• Treatment with an investigational drug within 1 month of Day 0 or current participation in another clinical trial.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Psoriasis

Intervention

Drug:
• WBI-1001
Comparison of two doses (0% and 1.0%) of the the WBI-1001 cream applied topically, twice daily for 12 weeks.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Welichem Biotech Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline (Day 0) in PGA in patients randomized to placebo as compared to patients randomized to 1.0% WBI-1001.	The primary indication of efficacy will be demonstrated by improvement in the Physician's Global Assessment (PGA) in patients treated with the active (1.0% WBI-1001) cream as compared with those treated with the placebo cream.	84 days	No
Secondary	Change in PASI score from baseline (Day 0) to Day 84 for patients in Group 1 compared with those in Group 2.	Change in the Psoriasis Area and Severity Index (PASI) score from the baseline (Day 0) at Day 84 in patients randomized to the placebo compared with those randomized to the 1.0% WBI-1001 cream treatment.	84 days	No
Secondary	Blood and urine analyses and vital signs assessments of patients from Day 0 to Day 84, and the follow-up at Day 112.	Comparative assessment of the laboratory analyses and vital signs of Group 1 and Group 2 patients from Day 0 to Day 84, and the follow-up at Day 112.	84 days plus 112 day follow-up.	Yes
Secondary	Change from baseline in BSA at Day 84 in patients randomized to placebo compared with those randomized to 1.0% WBI-1001 cream treatment.	Change in the BSA of involved skin (except for the face, scalp, groin and genital areas) from that at baseline (Day 0) to that at Day 84 when comparing patients in Group 1 with those in Group 2.	84 days	No
Secondary	Change from baseline (Day 0) in mean target lesion score at Day 84 in patients in Group 1 compared with those in Group 2.		84 days	No
Secondary	Change from baseline (Day 0)in target lesion induration at Day 84 in patients in Group 1 compared with those in Group 2.		84 days	No
Secondary	Change from baseline (Day 0) in target lesion scaling at Day 84 in patients in Group 1 compared with those in Group 2.		84 days	No
Secondary	Change from baseline (Day 0)in target lesion erythema at Day 84 in patients from Group 1 compared with those from Group 2.		84 days	No
Secondary	Type, frequency, severity and relationship of adverse events in patients from Group 1 compared with those from Group 2.		84 days + follow-up at 112 days	Yes